Business
OncBioMune Adds Capital Markets Leader Daniel Hoverman to Board of Directors
OncBioMune Adds Capital Markets Leader Daniel Hoverman to Board of Directors.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Adds Capital Markets Leader Daniel Hoverman to Board of Directors \n\nOncBioMune Adds Capital Markets Leader Daniel Hoverman to Board of Directors\n\n\n BATON ROUGE, LA--(Marketwired - January 05, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the appointment of Daniel Hoverman to the Company's Board of Directors, effective immediately. The addition of Mr. Hoverman expands OncBioMune's Board of Directors to five members.Daniel Hoverman is a Director at NYSE-listed Houlihan Lokey, a leading global investment bank, where he is a senior member of the firm's Corporate Finance Group. Mr. Hoverman is also actively involved with Houlihan Lokey's efforts in equity capital markets.\"Daniel is an accomplished leader with deep experience in the capital markets, including merger and acquisitions, finance and strategic partnerships. We are enthused to have him contribute his oversight abilities and expansive bandwidth to our Company. It is my pleasure to welcome him to our board,\" commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. \"Dan's skillset is a tremendous complement to Charles L. Rice, Jr., President and CEO of Entergy New Orleans, Inc., who joined our board last month, and will be a significant asset in helping us achieve our business goals.\"\"I am very pleased with the opportunity to serve as a Director at OncBioMune, a company that I believe has done very well to prudently manage resources and position itself for the future with its pioneering cancer technologies,\" said Daniel Hoverman. \"I have been involved with many transactions throughout my career that have been integral in corporate growth and greatly look forward to helping guide OncBioMune's strategy going forward.\"Mr. Hoverman has extensive mergers and acquisitions advisory and financing experience, having completed over $100 billion of transactions for both private and public companies across multiple industries and geographies. Before joining Houlihan Lokey, he was a Director with Credit Suisse in Hong Kong as a member of the office of the General Counsel, and was responsible for oversight and management of investm...